ReviewFrontiers in immunology2025
MicroRNAs as multifaceted regulators and therapeutic targets in ulcerative colitis.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expression patterns of miR-21 and miR-146 in ulcerative colitis: implications for disease progression and therapeutic strategies.Journal, genetic engineering & biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by mucosal barrier disruption, immune dysregulation, and gut microbiota imbalance. MicroRNAs (miRNAs), small non-coding regulators of gene expression, have emerged as pivotal modulators of UC pathogenesis. By orchestrating epithelial cell apoptosis, tight junction integrity, and mucin secretion, miRNAs such as miR-223, miR-151-5p, and miR-429 contribute to barrier dysfunction. Additionally, miRNAs shape the innate and adaptive immune responses by influencing macrophage polarization, dendritic cell maturation, and T cell subset differentiation, including Th17/Treg and Th1/Th2 balance. Specific miRNAs further modulate gut microbial composition and host-microbe interactions. Clinically, circulating miRNAs serve as promising non-invasive biomarkers for disease diagnosis, activity monitoring, and therapeutic response prediction. Therapeutically, miRNA mimics and inhibitors have shown efficacy in early-phase clinical trials, offering a novel strategy beyond current biologics. This review summarizes recent mechanistic insights and translational advances, underscoring the multifaceted roles of miRNAs in UC and their potential to inform precision diagnostics and targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.